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The efficacy of the human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against cervical infections with
HPV in the Papilloma Trial against Cancer in Young Adults (PATRICIA) was evaluated using a combination of the broad-spec-
trum L1-based SPF10 PCR-DNA enzyme immunoassay (DEIA)/line probe assay (LiPA25) system with type-specific PCRs for
HPV-16 and -18. Broad-spectrum PCR assays may underestimate the presence of HPV genotypes present at relatively low con-
centrations in multiple infections, due to competition between genotypes. Therefore, samples were retrospectively reanalyzed
using a testing algorithm incorporating the SPF10 PCR-DEIA/LiPA25 plus a novel E6-based multiplex type-specific PCR and re-
verse hybridization assay (MPTS12 RHA), which permits detection of a panel of nine oncogenic HPV genotypes (types 16, 18, 31,
33, 35, 45, 52, 58, and 59). For the vaccine against HPV types 16 and 18, there was nomajor impact on estimates of vaccine effi-
cacy (VE) for incident or 6-month or 12-month persistent infections when theMPTS12 RHAwas included in the testing algo-
rithm versus estimates with the protocol-specified algorithm. However, the alternative testing algorithm showed greater sensi-
tivity than the protocol-specified algorithm for detection of some nonvaccine oncogenic HPV types. More cases were gained in
the control group than in the vaccine group, leading to higher point estimates of VE for 6-month and 12-month persistent infec-
tions for the nonvaccine oncogenic types included in the MPTS12 RHA assay (types 31, 33, 35, 45, 52, 58, and 59). This post hoc
analysis indicates that the per-protocol testing algorithm used in PATRICIA underestimated the VE against some nonvaccine
oncogenic HPV types and that the choice of the HPVDNA testing methodology is important for the evaluation of VE in clinical
trials. (This study has been registered at ClinicalTrials.gov under registration no. NCT00122681.)
Persistent infection with oncogenic human papillomavirus(HPV) is a necessary prerequisite for the development of in-
vasive cervical cancer (ICC) (1). HPV type 16 (HPV-16) and
HPV-18 are found in approximately 70% of cases (2–5). Other
common oncogenic HPV types causing ICC include types 31, 33,
35, 45, 52, and 58 (2–5). GlaxoSmithKline Vaccines has developed
a prophylactic vaccine against HPV types 16 and 18, formulated
with the AS04 adjuvant system. This vaccine has been shown to be
immunogenic and efficacious and to have a clinically acceptable
safety profile (6–14).
In the large, randomized, double-blind, controlled Papilloma
Trial against Cancer in Young Adults (PATRICIA) (Clinical-
Trials.gov registration no. NCT00122681), the HPV-16/18 AS04-
adjuvanted vaccine prevented persistent infections and high-
grade cervical lesions associated with HPV types 16 and/or 18
(11–13) and showed high efficacy against cervical intraepithelial
February 2015 Volume 22 Number 2 cvi.asm.org 235Clinical and Vaccine Immunology
neoplasia grade 2 or greater (CIN2) and CIN3 irrespective of
the HPV type (13) and cross-protection against some phyloge-
netically related nonvaccine oncogenic HPV types (i.e., types 31,
33, 45, and 51) (12, 14). However, during both the event-triggered
final analysis and the end-of-study analysis of PATRICIA, nega-
tive point estimates of vaccine efficacy (VE) were observed for
other less common nonvaccine oncogenic HPV types (12, 14). In
particular, for 12-month persistent infections with HPV-58 in the
end-of-study analysis, the associated upper and lower 95% confi-
dence intervals (CIs) for VE were both less than zero (14), which
might potentially indicate an increase in either the incidence or
the duration of persistent infections with this genotype. On the
other hand, estimates of VE against histopathological endpoints
associated with HPV-58 were positive at the end-of-study analy-
sis, which would not be expected if the vaccine had caused a true
increase in the incidence or duration of persistent infection.
The present analysis investigated the hypothesis that the dis-
crepant efficacy results for persistent infection versus lesional end-
points for some nonvaccine HPV types might be due to a technical
issue in the PCR methodology used for HPV DNA detection (15).
The protocol-specified testing algorithm for PATRICIA included
the broad-spectrum L1-based SPF10 PCR DNA immunoassay
(DEIA) line probe assay (LiPA25) system (here referred to as SPF10
PCR-DEIA/LiPA25) and type-specific PCRs for HPV-16 and
HPV-18 (16, 17) but did not include type-specific PCRs for non-
vaccine HPV types. It is well recognized that broad-spectrum
PCRs are affected by competition between different HPV geno-
types present in the same sample and may underestimate the prev-
alence of genotypes present at low relative concentrations in mul-
tiple infections due to the differential efficiency of amplification
(16), a phenomenon that has been described as masking (18). In
theory, due to the efficacy of the vaccine in preventing infection
with HPV-16, HPV-18, and some nonvaccine oncogenic HPV
types (14), such a scenario is more likely to arise in the control
group than in the vaccine group, leading to a bias against the
vaccine.
To increase the sensitivity of HPV DNA detection for a larger
number of HPV genotypes, SPF10 PCR-DEIA-positive cervical
samples from PATRICIA were retrospectively reanalyzed using a
testing algorithm that combined the results from the broad-spec-
trum SPF10 PCR-DEIA/LiPA25 with a novel E6-based multiplex
type-specific PCR and reverse hybridization assay (designated
MPTS12 RHA), which permits detection of nine of the most com-
mon oncogenic HPV genotypes associated with ICC (HPV-16,
-18, -31, -33, -35, -45, -52, -58, and -59) (19). We report post hoc
end-of-study (month 48) estimates of VE against incident and
persistent infections using the alternative testing algorithm incor-
porating the MPTS12 RHA compared with those from the proto-
col-specified testing algorithm.
It is relevant to note that the purpose of this exploratory work
was to investigate a potential technical issue in the protocol-spec-
ified testing algorithm used in PATRICIA, rather than to draw
new conclusions regarding the efficacy of the HPV-16/18 AS04-
adjuvanted vaccine in the prevention of ICC. The previously re-
ported conclusions of PATRICIA, derived using the protocol-
specified HPV DNA testing algorithm (11–14), are still valid.
MATERIALS AND METHODS
The trial methods of PATRICIA have been described in detail (11, 12),
and the results of event-driven (12) and end-of-study (13, 14) analyses
were reported previously. The data described here are from the end-
of-study analysis after 48 months of follow-up. The protocol and other
materials were approved by independent ethics committees or institu-
tional review boards at each location. The study is registered with
ClinicalTrials.gov, number NCT00122681.
Participants. Healthy women aged 15 to 25 years with no more than
six lifetime sexual partners (this exclusion criterion was not applied in
Finland, in accordance with local regulatory and ethical requirements)
were included in the trial; the full inclusion and exclusion criteria, trial
locations, and dates were described previously (11, 12). Women were
included regardless of their baseline HPV DNA status, HPV-16 or
HPV-18 serostatus, or cytology. Written informed consent was ob-
tained from all adult participants. For minors, written informed assent
was obtained from the participants and from their parents.
Procedures. Women were randomized in a 1:1 ratio to receive either
the HPV-16/18 AS04-adjuvanted vaccine (Cervarix; GlaxoSmithKline
Vaccines) or control hepatitis A vaccine (GlaxoSmithKline Vaccines) at 0,
1, and 6 months in a double-blind manner. Cervical samples were ob-
tained every 6 months for HPV DNA detection and typing. Specimens
were stored in PreservCyt (Cytyc Corporation, Boxborough, MA) trans-
port medium. HPV DNA was extracted using the MagNA Pure LC system
(Roche Diagnostics, Almere, the Netherlands).
Protocol-specified algorithm forHPVDNAPCR testing.The proto-
col-specified HPV DNA testing algorithm combined the broad-spectrum
SPF10 PCR-DEIA/LiPA25 with the HPV-16 and HPV-18 type-specific
(TS) PCR (16). The SPF10 PCR-DEIA and LiPA25 version 1 are produced
by Labo Biomedical Products (Rijswijk, the Netherlands) and are based
on licensed Innogenetics technology.
The SPF10 PCR primer set, which amplifies a 65-nucleotide region of
the HPV L1 gene, was used to amplify a broad spectrum of HPV genotypes
(20, 21). After generic amplification, hybridization was done with a cock-
tail of nine conservative HPV probes using a DNA enzyme immunoassay
(DEIA) recognizing at least 64 different HPV genotypes. SPF10 amplimers
from HPV-positive clinical samples from PATRICIA were then geno-
typed using reverse hybridization on a line probe assay (LiPA) containing
probes for 25 different HPV genotypes: 14 oncogenic HPV types (16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) and 11 nononcogenic HPV
types (6, 11, 34, 40, 42, 43, 44, 53, 54, 70, and 74). If the SPF10 LiPA25
detected no HPV-16, the specimen was tested by the HPV-16 TS PCR (a
type-specific PCR which used primers that amplified a 92-nucleotide seg-
ment of the E6/E7 gene). Likewise, if the SPF10 LiPA25 detected no HPV-
18, the specimen was tested by the HPV-18 TS PCR (which used primers
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that amplified a 126-nucleotide segment of the L1 gene). The cervical
sample was considered positive for a particular HPV type if either the
SPF10 PCR-DEIA/LiPA25 or the HPV-16/18 TS PCR or both (the SPF10
PCR-DEIA/LiPA25 plus HPV-16/18 TS-PCR) had a positive result for the
HPV type.
Post hoc algorithm for HPV DNA PCR testing. Following comple-
tion of the PATRICIA end-of-study analysis, the cervical samples (but not
the biopsy specimens) were reanalyzed using an HPV DNA PCR testing
algorithm that included the validated MPTS12 RHA assay (19). The per-
sonnel involved in the retesting were blinded to the results of the protocol-
specified HPV DNA PCR testing.
The first part of the post hoc algorithm was the same as that defined for
the protocol-specified algorithm, i.e., SPF10 PCR-DEIA-positive samples
were genotyped using a LiPA. In addition, the SPF10 PCR-DEIA-positive
samples were genotyped using the MPTS12 PCR RHA system (Labo Bio-
medical Products, BV, Rijswijk, the Netherlands). The MPTS12 RHA de-
tects and genotypes nine oncogenic HPV types (16, 18, 31, 33, 35, 45, 52,
58, and 59), even at very low copy numbers and in the presence of multiple
infections in cervical liquid-based cytology samples, offering high sensi-
tivity and specificity.
The MPTS12 RHA includes two sets of multiplex PCRs, one for HPV
types 18, 31, 33, and 35 (MPTS1) and the other for types 16, 45, 52, 58, and
59 (MPTS2). In both the MPTS1 and MPTS2, each HPV type was specif-
ically amplified by a pair of single reverse and single forward primers from
the HPV E6 region. To analyze the PCR products generated by the two
multiplex PCR mixes, the system used a strip-based reverse hybridization
assay (RHA), hybridizing to 10 type-specific HPV probes which recognize
the interprimer region of the MPTS1 and/or MPTS2 strand.
The cervical sample was considered positive for a particular HPV type
if after SPF10 PCR-DEIA positivity either the SPF10 PCR-DEIA/LiPA25 or
the MPTS12 RHA or both (SPF10 PCR-DEIA/LiPA25 plus MPTS12 RHA)
had a positive result. For nonvaccine oncogenic HPV types, the testing
algorithm, SPF10 PCR-DEIA/LiPA25 plus MPTS12 RHA, has been shown
to increase the sensitivity of detection for all SPF10 PCR-DEIA/LiPA25
plus MPTS12 RHA-detectable genotypes, including HPV-58 and HPV-
59, compared with that of either of the two tests alone (19).
Statistical analysis. To allow comparisons with previously published
results from PATRICIA (12, 14), endpoints were evaluated in three co-
horts: the according-to-protocol cohort for efficacy (ATP-E), the total
vaccinated cohort (TVC), and the TVC-naive. Licensure of the vaccine
was based on the analysis of the ATP-E to fully describe the vaccine’s
profile (12); therefore, the ATP-E is considered the primary cohort for the
analyses described here. Supplementary analyses are presented for the
TVC and TVC-naive for comparison with previous publications and be-
cause these cohorts are more relevant from a public health perspective.
The ATP-E included women who were evaluable for efficacy (i.e., had a
baseline PCR or cytology sample and one further sample available), met
all of the eligibility criteria, complied with the protocol, received all three
vaccine doses, and had negative or low-grade cytology at baseline. In the
ATP-E, endpoints were assessed in women who were HPV DNA negative
at months 0 and 6 for the HPV type analyzed. The TVC included all
women who received at least one vaccine dose and were evaluable for
efficacy. Endpoints were assessed in the TVC irrespective of a women’s
baseline HPV DNA, cytological status, or serostatus. The TVC-naive in-
cluded women who had received at least one vaccine dose, who were
evaluable for efficacy, and who at baseline were HPV DNA negative for the
14 oncogenic HPV types, were seronegative for HPV-16 and HPV-18, and
had negative cytology.
We report VE against incident and 6-month and 12-month persistent
infections for each of the nine oncogenic HPV types which can be geno-
typed using the MPTS12 RHA (i.e., HPV-16, -18, -31, -33, -35, -45, -52,
-58, and -59). We also report VE for the composite endpoint of all 14
oncogenic HPV types which can be genotyped using the LiPA25 (i.e.,
HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66, and -68)
and for the composite of nonvaccine oncogenic HPV types (i.e., HPV-31,
-33, -35, -39, -45, -51, -52, -56, -58, -59, -66, and -68). Six-month persis-
tent infection was defined as the detection of the same HPV type by PCR
at two consecutive evaluations over approximately a 6-month interval.
Twelve-month persistent infection was defined as the detection of the
same HPV type by PCR at all available time points over approximately a
12-month interval. Results are reported for the protocol-specified HPV
DNA testing algorithm (SPF10 PCR-DEIA/LiPA25 plus HPV-16/18 TS-
PCR) and the alternative HPV DNA testing algorithm (SPF10 PCR-DEIA/
LiPA25 plus MPTS12 RHA). It was not appropriate to statistically com-
pare estimates of VE derived from the two testing algorithms, since the
two estimates were based on data obtained from the same individuals and
were not independent.
VE and 95% confidence intervals (CIs) were calculated using a condi-
tional exact method (14). Results with the protocol-specified testing
method were considered to confirm the statistically significant VE ob-
served in the final event-driven analysis (12) if end-of-study estimates of
VE and their 95% CIs were greater than zero. Event rates were calculated
as the number of cases divided by the total follow-up in years and are
expressed per 100 person-years. In the ATP-E, follow-up started the day
after the third vaccine dose. In the TVC, follow-up started the day after the
first vaccine dose. Follow-up for each outcome ended at the time the
outcome occurred or at the last available sample (up to month 48).
The absolute change () in the number of cases of infection was cal-
culated as the number of cases detected using the alternative testing algo-
rithm minus the number detected using the protocol-specified testing
algorithm. The relative difference in the number of cases (%  cases) was
calculated as  divided by the number of cases detected using the proto-
col-specified testing algorithm 100. The relative difference in terms of
person-year rates is also reported (%  rates).
Statistical analyses were done with SAS version 9.2 and Proc
StatXact-7 on Windows XP.
RESULTS
At the time of the PATRICIA end-of study analysis, a total of
18,644 women (vaccine n  9,319, control n  9,325) were in-
cluded in the TVC, 16,114 women (vaccine n 8,067, control n
8,047) in the ATP-E, and 11,644 women (vaccine n 5,824, con-
trol n  5,820) in the TVC-naive (13, 14). The entire subset of
SPF10 PCR-DEIA-positive samples (17,500 samples) from the
end-of-study analysis were reanalyzed using the MPTS12 RHA.
Additional cases of 12-month persistent infection, 6-month
persistent infection, and incident infection were detected in all
cohorts when the MPTS12 RHA was included in the testing algo-
rithm for the composite endpoints of any nonvaccine oncogenic
HPV type and any oncogenic HPV type (Table 1). The absolute
number of cases gained was largest in the TVC. For all cohorts, the
relative difference between the two algorithms in the number of
cases gained (%  cases) and in the rate of infection adjusted for
duration of follow-up (%  rates) was larger for any nonvac-
cine oncogenic HPV type than for any oncogenic HPV type and
was larger for persistent infections than for incident infections
(Table 1).
In the ATP-E, more cases were gained in the control group
than in the vaccine group for each of the composite endpoints,
e.g., for any nonvaccine oncogenic HPV type, the relative in-
creases in the numbers of cases (% cases) in the control and
vaccine groups, respectively, were 8.4 versus 4.5 for 12-month
persistence, 4.4 versus 1.9 for 6-month persistence, and 2.2 versus
1.7 for incident infection (Table 1). In the TVC and TVC-naive,
the differential between the control and vaccine groups in terms of
the relative increase in the number of cases of any nonvaccine
oncogenic HPV type was not as large as it was in the ATP-E, and
for any oncogenic HPV type (including types 16 and 18), the rel-
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ative increase in the number of cases tended to be larger in the
vaccine group than in the control group (Table 1).
In the ATP-E for vaccine HPV types, a few cases were gained
(HPV-18) or lost (HPV-16) with inclusion of the MPTS12 RHA
versus the HPV-16/18 TS PCR in the testing algorithm, without a
major impact on the estimates of VE for 12-month persistent in-
fection (Table 2), 6-month persistent infection (Table 3), or inci-
dent infection (Table 4). In the ATP-E for individual nonvaccine
oncogenic HPV types included in the MPTS12 RHA, the relative
difference in the number of cases (%  cases) of 12-month or
6-month persistent infections was higher in the control group
than in the vaccine group for all genotypes, leading to higher point
estimates of VE for these nonvaccine HPV types (Tables 2 and 3,
respectively). The gain in cases of persistent infection detected by
the alternative algorithm incorporating the MPTS12 RHA was
particularly large for HPV-45, HPV-58, and HPV-59. For incident
infection, the relative change in the number of cases detected was
generally similar between the control and vaccine groups, except
for HPV-45 and HPV-58; therefore, no major impact on the esti-
mates of VE against incident infection was observed for most of
the individual nonvaccine HPV types when the MPTS12 RHA was
included in the HPV DNA testing algorithm (Table 4). Differen-
tials between vaccine and control groups in terms of relative in-
creases in the number of cases of individual nonvaccine HPV types
tended to be less marked in the TVC (see Tables S1 to S3 in the
supplemental material) and in the TVC-naive (see Tables S4 to S6
in the supplemental material) than in the ATP-E.
The reanalysis of samples from PATRICIA was driven by the
negative estimate of VE observed for 12-month persistent infec-
tion with HPV-58 using the protocol-specified testing algorithm,
for which the associated 95% CI did not include zero. On a com-
parison of the prespecified testing algorithm versus the alternative
algorithm, the estimate for VE against 12-month persistent infec-
tion with HPV-58 in the ATP-E increased from54.1% (121.3
to8.1) to2.9% (35.4 to 21.7), with an additional 28 and 54
cases detected in the vaccine and control groups, respectively (Ta-
ble 2). The estimate for VE against 6-month persistent infection
with HPV-58 increased from 18.3% (51.8 to 7.7) to 8.2%
(12.9 to 25.4), with an additional 37 and 75 cases detected in the
vaccine and control groups, respectively (Table 3).
Significant VE was already observed against persistent infec-
tions with HPV-31 and HPV-45 when the protocol-specified test-
ing algorithm was used (Tables 2 and 3). For HPV-31, the relative
differences in the number of cases in the ATP-E using the alterna-
tive testing algorithm in the control and vaccine groups were
11.0% versus 6.7% for 12-month persistent infection and 8.9%
versus6.9% for 6-month persistent infection, respectively, and
there was no major impact on VE. For HPV-45, the relative dif-
ference in the number of cases was much larger in the control
group than in the vaccine group (68.8% versus 7.7% for 12-
month persistent infection; 38.9% versus 0% for 6-month persis-
tent infection), resulting in an increase in VE.
DISCUSSION
Detection and identification of HPV genotypes in cervical samples
and biopsy specimens are dependent on the accuracy and preci-
sion of the methods used. As vaccine trials use surrogate virolog-
ical endpoints such as incident and persistent infection, in addi-
tion to histological endpoints, to predict vaccine efficacy, it is
important that testing methods be reliable and robust. In this
6-
m
on
th
P
I
N
on
va
cc
in
e
H
R
-H
P
V
V
ac
ci
n
e
5,
42
7
90
7
4.
84
19
.0
(1
1.
5,
25
.9
)

0.
00
01
5,
41
0
93
4
5.
02
19
.5
(1
2.
2,
26
.3
)

0.
00
01

27
3.
0
3.
7
C
on
tr
ol
5,
39
9
1,
08
7
5.
98
5,
36
9
1,
12
2
6.
24

35
3.
2
4.
4
H
R
-H
P
V
V
ac
ci
n
e
5,
42
7
92
5
4.
95
33
.1
(2
7.
1,
38
.5
)

0.
00
01
5,
41
0
95
1
5.
13
31
.8
(2
5.
8,
37
.3
)

0.
00
01

26
2.
8
3.
5
C
on
tr
ol
5,
39
9
1,
30
7
7.
40
5,
36
9
1,
31
7
7.
52

10
0.
8
1.
6
In
ci
de
n
t
N
on
va
cc
in
e
H
R
-H
P
V
V
ac
ci
n
e
5,
56
8
1,
94
0
11
.3
0
13
.4
(7
.9
,1
8.
6)

0.
00
01
5,
54
9
1,
96
2
11
.5
2
13
.9
(8
.4
,1
9.
0)

0.
00
01

22
1.
1
1.
9
C
on
tr
ol
5,
55
9
2,
17
3
13
.0
4
5,
52
6
2,
20
2
13
.3
7

29
1.
3
2.
5
H
R
-H
P
V
V
ac
ci
n
e
5,
56
8
2,
02
0
11
.8
8
19
.9
(1
5.
0,
24
.5
)

0.
00
01
5,
54
9
2,
03
8
12
.0
8
19
.8
(1
4.
9,
24
.4
)

0.
00
01

18
0.
9
1.
6
C
on
tr
ol
5,
55
9
2,
39
6
14
.8
3
5,
52
6
2,
40
9
15
.0
5

13
0.
5
1.
5
a
N
o.
,n
u
m
be
r
of
ev
al
u
ab
le
w
om
en
in
ea
ch
gr
ou
p;
P
I,
pe
rs
is
te
n
t
in
fe
ct
io
n
;C
as
es
,n
u
m
be
r
of
w
om
en
re
po
rt
in
g
at
le
as
t
on
e
ev
en
t
in
ea
ch
gr
ou
p;
R
at
e,
n
u
m
be
r
of
ca
se
s
di
vi
de
d
by
th
e
su
m
of
th
e
fo
llo
w
-u
p
pe
ri
od
(p
er
10
0
w
om
an
ye
ar
s)
(f
ol
lo
w
-u
p
st
ar
te
d
on
th
e
da
y
af
te
r
th
e
th
ir
d
va
cc
in
e
do
se
fo
r
th
e
A
T
P
-E
an
d
on
th
e
da
y
af
te
r
th
e
fi
rs
t
va
cc
in
e
do
se
fo
r
th
e
T
V
C
an
d
T
V
C
-n
ai
ve
);
V
E
(%
),
va
cc
in
e
ef
fi
ca
cy
(c
on
di
ti
on
al
ex
ac
t
m
et
h
od
);
N
on
va
cc
in
e
H
R
-H
P
V
,a
n
y
n
on
va
cc
in
e
h
ig
h
-r
is
k
(o
n
co
ge
n
ic
)
H
P
V
ty
pe
(H
P
V
-3
1,
-3
3,
-3
5,
-3
9,
-4
5,
-5
1,
-5
2,
-5
6,
-5
8,
-5
9,
-6
6,
an
d
-6
8)
;H
R
-H
P
V
,a
n
y
h
ig
h
-r
is
k
(o
n
co
ge
n
ic
)
H
P
V
ty
pe
s
(H
P
V
-1
6,
-1
8,
-3
1,
-3
3,
-3
5,
-3
9,
-4
5,
-5
1,
-5
2,
-5
6,
-5
8,
-5
9,
-6
6,
an
d
-6
8)
;
ca
se
s,
ab
so
lu
te
di
ff
er
en
ce
of
n
u
m
be
r
of
ca
se
s

n
u
m
be
r
of
ca
se
s
de
te
rm
in
ed
by
th
e
al
te
rn
at
iv
e
al
go
ri
th
m

n
u
m
be
r
of
ca
se
s
de
te
rm
in
ed
by
th
e
pr
ot
oc
ol
-s
pe
ci
fi
ed
al
go
ri
th
m
;%

ca
se
s,
re
la
ti
ve
di
ff
er
en
ce
of
n
u
m
be
r
of
ca
se
s



10
0/
(n
u
m
be
r
of
ca
se
s
de
te
rm
in
ed
by
th
e
pr
ot
oc
ol
-s
pe
ci
fi
ed
al
go
ri
th
m
);
%

ra
te
s,
re
la
ti
ve
di
ff
er
en
ce
of
ra
te
s

(r
at
e
de
te
rm
in
ed
by
th
e
al
te
rn
at
iv
e
al
go
ri
th
m

ra
te
de
te
rm
in
ed
by
th
e
pr
ot
oc
ol
-s
pe
ci
fi
ed
al
go
ri
th
m
)

10
0/
(r
at
e
de
te
rm
in
ed
by
th
e
pr
ot
oc
ol
-s
pe
ci
fi
ed
al
go
ri
th
m
).
b
T
h
e
A
T
P
-E
an
al
ys
is
w
as
co
n
du
ct
ed
fo
r
w
om
en
w
h
o
w
er
e
H
P
V
D
N
A
n
eg
at
iv
e
fo
r
th
e
co
rr
es
po
n
di
n
g
H
P
V
ty
pe
at
m
on
th
s
0
an
d
6.
c
T
h
e
T
V
C
an
al
ys
is
w
as
co
n
du
ct
ed
fo
r
al
lw
om
en
,i
rr
es
pe
ct
iv
e
of
th
ei
r
ba
se
lin
e
H
P
V
D
N
A
st
at
u
s.
d
T
h
e
T
V
C
-n
ai
ve
an
al
ys
is
w
as
co
n
du
ct
ed
fo
r
w
om
en
w
h
o
w
er
e
D
N
A
n
eg
at
iv
e
fo
r
al
l1
4
h
ig
h
-r
is
k
H
P
V
ty
pe
s
an
d
se
ro
n
eg
at
iv
e
fo
r
H
P
V
-1
6
an
d
H
P
V
-1
8
an
d
h
ad
n
eg
at
iv
e
cy
to
lo
gy
at
m
on
th
0.
Choice of HPV DNA Testing Algorithm in Vaccine Trials
February 2015 Volume 22 Number 2 cvi.asm.org 239Clinical and Vaccine Immunology
exploratory post hoc analysis, we retested cervical samples from
PATRICIA, incorporating a recently developed E6-based multi-
plex type-specific PCR and reverse hybridization assay (desig-
nated MPTS12 RHA) in the HPV DNA testing algorithm (19). We
showed that for some nonvaccine oncogenic HPV types, a large
number of additional cases of persistent infection were detected
when the MPTS12 RHA was utilized compared with the number
detected with the protocol-specified testing algorithm. In the
ATP-E, the relative increase in additional cases was larger in the
control group than in the vaccine group, resulting in an increase in
VE for persistent infection with some of these HPV types (e.g.,
HPV-45 and HPV-58 and to a lesser extent HPV-59 and HPV-33).
The reevaluation of virological endpoints in PATRICIA, using
the recently developed MPTS12 RHA (19), was initiated in re-
sponse to the finding of negative VE against persistent infection
for some nonvaccine oncogenic HPV types, e.g., HPV-58 (14).
One possible explanation was a potential bias against the vaccine
due to technicalities in the PCR methodology used for HPV DNA
testing (15). The broad-spectrum L1-based SPF10 PCR-DEIA sys-
tem has 10 primers that target relatively well-conserved genomic
sequences, permitting the simultaneous amplification of at least
64 HPV genotypes in a single test. However, competition can oc-
cur between multiple HPV types present in the same sample, and
genotypes present at low concentrations can remain unde-
tected as they are outcompeted by genotypes present at high
concentrations (16).
Mixed infections with more than one HPV type were com-
monly observed in PATRICIA and were more common in the
control group than in the vaccine group because of the efficacy of
the vaccine in preventing infections with HPV-16, HPV-18, and
some other oncogenic HPV types (14). Genotyping of SPF10 PCR-
DEIA-positive samples using the E6-based MPTS12 RHA is
known to be less prone to loss of sensitivity in the presence of
multiple infections due to the use of individual primer sets specific
for each of the nine genotypes (types 16, 18, 31, 33, 35, 45, 52, 58,
and 59) included in the assay. In a previous evaluation, the com-
bination of the SPF10 PCR-DEIA/LiPA25 plus MPTS12 RHA sys-
tems resulted in a 14.3% increase in the detection of HPV geno-
types compared with those detected by the SPF10 PCR-DEIA/
LiPA25 system alone (19). Additionally, during progression from a
low-grade lesion to a high-grade lesion or ICC, the HPV genome
can integrate into the host DNA, and portions of the L1 and other
HPV genes may be lost, whereas E6/E7 is retained (22). Thus,
testing methods based on both early (E) and late (L) genes such
TABLE 2 Vaccine efficacy against 12-month persistent infection in HPV DNA-negative subjects at months 0 and 6 (ATP-E)a
HPV type Group
Results for protocol-specified HPV DNA testing
algorithm (SPF10 PCR-DEIA/LiPA25HPV-16/18
TS-PCR):
Results for alternative HPV DNA testing algorithm
(SPF10 PCR-DEIA/LiPA25MPTS12 RHA):
Results for additional
cases (alternative
algorithm protocol-
specified algorithm):
No. Cases Rate VE (95% CI) P value No. Cases Rate VE (95% CI) P value  cases
% 
cases
% 
(rates)
HPV-16 Vaccine 7,103 20 0.08 93.6 (89.9 to 96.1) 0.0001 7,106 18 0.08 93.9 (90.2 to 96.4) 0.0001 2 10.0 10.1
Control 6,996 300 1.30 6,994 284 1.23 16 5.3 5.4
HPV-18 Vaccine 7,356 8 0.03 92.4 (84.4 to 96.8) 0.0001 7,346 12 0.05 89.1 (80.1 to 94.5) 0.0001 4 50.0 50.3
Control 7,288 103 0.42 7,284 108 0.44 5 4.9 4.9
HPV-31 Vaccine 7,295 30 0.12 78.1 (67.2 to 85.7) 0.0001 7,277 32 0.13 79.0 (69.1 to 86.1) 0.0001 2 6.7 7.0
Control 7,309 136 0.56 7,279 151 0.62 15 11.0 11.7
HPV-33 Vaccine 7,426 38 0.15 35.8 (1.9 to 58.5) 0.0326 7,410 47 0.19 40.8 (14.0 to 59.6) 0.0041 9 23.7 24.1
Control 7,404 59 0.24 7,385 79 0.32 20 33.9 34.5
HPV-35 Vaccine 7,468 37 0.15 42.6 (145.2 to 16.0) 0.2064 7,463 38 0.15 41.0 (140.2 to 16.1) 0.2135 1 2.7 2.8
Control 7,462 26 0.10 7,459 27 0.11 1 3.8 3.9
HPV-45 Vaccine 7,485 13 0.05 59.6 (20.8 to 80.5) 0.0044 7,446 12 0.05 78.0 (58.3 to 89.3) 0.0001 1 7.7 7.2
Control 7,445 32 0.13 7,400 54 0.22 22 68.8 70.0
HPV-52 Vaccine 7,185 200 0.84 3.0 (18.5 to 20.6) 0.7624 7,146 221 0.93 6.1 (13.4 to 22.2) 0.5049 21 10.5 11.3
Control 7,134 205 0.87 7,102 234 0.99 29 14.1 15.0
HPV-58 Vaccine 7,411 83 0.33 54.1 (121.3 to8.1) 0.0159 7,335 111 0.45 2.9 (35.4 to 21.7) 0.8917 28 33.7 35.5
Control 7,403 54 0.22 7,335 108 0.44 54 100.0 102.8
HPV-59 Vaccine 7,425 27 0.11 35.2 (154.3 to 26.9) 0.3809 7,338 58 0.24 29.2 (95.1 to 14.0) 0.2,353 31 114.8 118.0
Control 7,422 20 0.08 7,333 45 0.18 25 125.0 128.2
a No., number of evaluable women in each group; Cases, number of women reporting at least one event in each group; Rate, number of cases divided by the sum of the follow-up
period (per 100 woman years) (the follow-up period started on the day after the third vaccine dose); VE (%), vaccine efficacy (conditional exact method). Women had to be DNA
negative for the corresponding HPV type at months 0 and 6.  cases, absolute difference of number of cases number of cases determined by the alternative algorithm number
of cases determined by the protocol-specified algorithm; %  cases, relative difference of number of cases  100/(number of cases determined by the protocol-specified
algorithm); %  rates, relative difference of rates (rate determined by the alternative algorithm rate determined by the protocol-specified algorithm) 100/(rate determined
by the protocol-specified algorithm).
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as the L1-based PCR-DEIA/LiPA25 plus E6-based MPTS12
RHA can potentially detect HPV when deletions in the HPV
genome have been introduced as a result of integration into
cellular DNA (22).
When the alternative HPV DNA testing algorithm incorporat-
ing the MPTS12 RHA was used, there was no major impact on the
estimates of VE for virological endpoints associated with HPV-16
and HPV-18. This was expected, as the MPTS12 RHA showed
similar sensitivities to HPV-16 and HPV-18 TS PCRs during assay
validation (19). Only a few cases of HPV-16 or HPV-18 were
gained or lost using the alternative testing algorithm, and the high
VE observed against vaccine HPV types using the protocol-spec-
ified algorithm was not affected by these subtle technical issues. It
is not known if the cases which were gained or lost had low copy
numbers, but aliquot effects alone might explain these small dif-
ferences in detection rates. The nonvaccine oncogenic HPV types
with lower observed estimates of VE might be expected to be af-
fected to a greater extent by technical diagnostic issues. Indeed,
using the alternative testing algorithm, the proportion of addi-
tional cases of persistent infection with nonvaccine oncogenic
HPV types was higher in the control group than in the vaccine
group, leading to higher estimates of VE for all nonvaccine geno-
types included in the MPTS12 RHA. It should be noted that no
adjustment was made for multiple comparisons, and small in-
creases in VE might arise by chance. However, the large differ-
ences observed for some genotypes (e.g., HPV-45 and HPV-58)
are unlikely to be due to chance.
The differential detection of nonvaccine oncogenic HPV geno-
types in the control group versus the vaccine group in the ATP-E
using the alternative HPV DNA testing algorithm was greater for
some genotypes (e.g., HPV-45 and HPV-58) than for others (e.g.,
HPV-31). This may reflect differences in viral concentration
(“load”) for genotypes such as HPV-45 or HPV-58, which may be
present in lower concentrations than HPV-31. The HPV types at
lower concentrations in a mixed infection would be less likely to
be detected by the SPF10 PCR-DEIA/LiPA25 (high proportion of
false negatives) but would be detected using the more sensitive
MPTS12 RHA. In contrast, the HPV types at higher concentra-
tions in a mixed infection may still be detected by the SPF10 PCR-
DEIA/LiPA25 (low proportion of false negatives). Therefore, the
addition of the MPTS12 RHA to the testing algorithm would have
a lesser impact. We do not have viral load data and thus cannot test
this hypothesis. Alternatively, the competition effects might be
greater for some HPV types due to the extent of similarity between
TABLE 3 Vaccine efficacy against 6-month persistent infection in HPV DNA-negative subjects at months 0 and 6 (ATP-E)a
HPV type Group
Results for protocol-specified HPV DNA testing
algorithm (SPF10 PCR-DEIA/LiPA25HPV-16/18
TS-PCR):
Results for alternative HPV DNA testing algorithm
(SPF10 PCR-DEIA/LiPA25MPTS12 RHA):
Results for additional
cases (alternative
algorithm protocol-
specified algorithm):
No. Cases Rate VE (95% CI) P value No. Cases Rate VE (95% CI) P value  cases
% 
cases
% 
(rates)
PV-16 Vaccine 7,202 31 0.13 93.8 (91.0 to 95.8) 0.0001 7,204 30 0.12 93.7 (90.9 to 95.8) 0.0001 1 3.2 3.3
Control 7,099 473 2.07 7,097 456 1.99 17 3.6 3.7
HPV-18 Vaccine 7,465 14 0.06 94.0 (89.7 to 96.8) 0.0001 7,455 17 0.07 92.9 (88.4 to 95.9) 0.0001 3 21.4 21.7
Control 7,394 227 0.93 7,390 234 0.96 7 3.1 3.2
HPV-31 Vaccine 7,400 58 0.24 76.8 (69.0 to 82.9) 0.0001 7,382 54 0.22 80.2 (73.4 to 85.5) 0.0001 4 6.9 6.7
Control 7,414 247 1.01 7,383 269 1.11 22 8.9 9.6
HPV-33 Vaccine 7,534 65 0.26 44.8 (24.6 to 59.9) 0.0001 7,518 80 0.32 50.7 (35.2 to 62.8) 0.0001 15 23.1 23.5
Control 7,513 117 0.47 7,494 161 0.65 44 37.6 38.5
HPV-35 Vaccine 7,579 67 0.27 19.8 (74.1 to 17.2) 0.3654 7,573 68 0.27 9.9 (57.6 to 23.3) 0.6598 1 1.5 1.6
Control 7,569 56 0.22 7,565 62 0.25 6 10.7 10.8
HPV-45 Vaccine 7,594 24 0.09 73.6 (58.1 to 83.9) 0.0001 7,554 24 0.10 81.0 (70.5 to 88.3) 0.0001 0 0.0 0.5
Control 7,556 90 0.36 7,509 125 0.50 35 38.9 40.1
HPV-52 Vaccine 7,289 346 1.46 8.3 (6.5 to 21.0) 0.2515 7,250 364 1.55 12.9 (0.6 to 24.5) 0.0553 18 5.2 6.0
Control 7,237 374 1.59 7,203 414 1.78 40 10.7 11.6
HPV-58 Vaccine 7,518 144 0.58 18.3 (51.8 to 7.7) 0.1938 7,441 181 0.74 8.2 (12.9 to 25.4) 0.4345 37 25.7 27.4
Control 7,511 122 0.49 7,442 197 0.80 75 61.5 64.1
HPV-59 Vaccine 7,536 73 0.29 7.5 (51.8 to 23.8) 0.7352 7,446 135 0.55 2.1 (25.1 to 23.3) 0.8548 62 84.9 88.1
Control 7,530 68 0.27 7,440 138 0.56 70 102.9 106.5
a No., number of evaluable women in each group; Cases, number of women reporting at least one event in each group; Rate, number of cases divided by the sum of the follow-up
period (per 100 woman years) (the follow-up period started on the day after the third vaccine dose); VE (%), vaccine efficacy (conditional exact method). Women had to be DNA
negative for the corresponding HPV type at months 0 and 6.  cases, absolute difference of number of cases number of cases determined by the alternative algorithm number
of cases determined by the protocol-specified algorithm; %  cases, relative difference of number of cases  100/(number of cases determined by the protocol-specified
algorithm); %  rates, relative difference of rates (rate determined by the alternative algorithm rate determined by the protocol-specified algorithm) 100/(rate determined
by the protocol-specified algorithm).
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the DNA sequences of different HPV types detected by the SPF10
PCR primer set.
The increase in the absolute number of cases detected using the
new testing algorithm was larger in the TVC than in the ATP-E
because case counting started after dose 1 instead of dose 3 and
also because there were fewer conditions that had to be fulfilled for
a subject to be included in the TVC. The TVC includes all women
for whom efficacy data were available, regardless of their baseline
HPV or cytological status, while women in the ATP-E had to be
HPV DNA negative for the corresponding HPV type at months 0
and 6 to have complied with the protocol and have normal or
low-grade cytology at month 0. Thus, compared to the ATP-E, the
TVC also includes cases resulting from prevalent infections at
baseline. Since prevalent infections at baseline can be assumed to
be roughly equally distributed between the two groups and the
vaccine does not have a therapeutic effect, we expected to observe
relatively more cases in the vaccine group than in the control
group when comparing the TVC versus ATP-E, and this was in-
deed the case.
The addition of the MPTS12 RHA to the testing algorithm
appears to have a greater impact on the rate of infection and asso-
ciated VE for persistent infections than for incident infections.
This is because when multiple independent samples from the
same subject are tested over time (with samples being collected at
approximately 6-month intervals), there is an increasing chance
that one of the samples will be a coinfection in which a vaccine-
preventable HPV type is masked when tested using the proto-
col-specified algorithm. For example, if the HPV type was
masked in one of two consecutive samples, the case would not
meet the definition for persistent infection but would still meet
the definition for incident infection. When the testing algo-
rithm incorporating type-specific MPTS12 RHA is used, the
HPV type would be detected in both samples and counted as an
additional case of persistent infection.
We recognize that there are several other factors that may
have contributed to the negative estimates of VE observed in
PATRICIA, including a chance finding, an artifact of the col-
poscopy referral algorithm biasing against the vaccine, or HPV
type replacement. We conducted additional exploratory statis-
tical analyses to evaluate the likelihood of a chance finding (by
adjusting for multiplicity) or bias due to the colposcopy refer-
ral algorithm (by conducting sensitivity analyses) and con-
cluded that these factors were unlikely to explain the negative
estimates of VE. While there is a theoretical concern that on-
TABLE 4 Vaccine efficacy against incident infection in HPV DNA-negative subjects at months 0 and 6 (ATP-E)a
HPV type Group
Results for protocol-specified HPV DNA testing
algorithm (SPF10 PCR-DEIA/LiPA25HPV-16/18
TS-PCR):
Results for alternative HPV DNA testing algorithm
(SPF10 PCR-DEIA/LiPA25MPTS12 RHA):
Results for additional
cases (alternative
algorithm protocol-
specified algorithm):
No. Cases Rate VE (95% CI) P value No. Cases Rate VE (95% CI) P value  cases
% 
cases
% 
(rates)
HPV-16 Vaccine 7,361 170 0.71 82.9 (79.9 to 85.6) 0.0001 7,365 172 0.72 82.3 (79.2 to 85.1) 0.0001 2 1.2 1.1
Control 7,273 936 4.17 7,272 915 4.07 21 2.2 2.3
HPV-18 Vaccine 7,637 182 0.73 74.1 (69.4 to 78.1) 0.0001 7,625 169 0.68 75.5 (70.9 to 79.4) 0.0001 13 7.1 7.1
Control 7,583 676 2.83 7,579 664 2.78 12 1.8 1.8
HPV-31 Vaccine 7,574 204 0.83 68.9 (63.6 to 73.6) 0.0001 7,553 216 0.88 68.8 (63.5 to 73.3) 0.0001 12 5.9 6.2
Control 7,598 642 2.67 7,567 674 2.82 32 5.0 5.7
HPV-33 Vaccine 7,711 173 0.69 50.5 (40.4 to 59.0) 0.0001 7,695 201 0.80 48.4 (38.7 to 56.7) 0.0001 28 16.2 16.6
Control 7,706 346 1.39 7,687 385 1.56 39 11.3 11.9
HPV-35 Vaccine 7,758 166 0.66 26.2 (9.4 to 40.0) 0.0029 7,752 179 0.71 23.1 (6.2 to 37.1) 0.0081 13 7.8 8.0
Control 7,763 225 0.89 7,758 233 0.93 8 3.6 3.7
HPV-45 Vaccine 7,772 73 0.29 76.0 (68.9 to 81.7) 0.0001 7,727 115 0.46 69.5 (62.3 to 75.5) 0.0001 42 57.5 58.8
Control 7,744 300 1.20 7,692 370 1.49 70 23.3 24.7
HPV-52 Vaccine 7,453 825 3.55 13.4 (4.9 to 21.2) 0.0017 7,414 874 3.80 13.5 (5.2 to 21.1) 0.0011 49 5.9 7.0
Control 7,415 945 4.10 7,381 1,002 4.39 57 6.0 7.0
HPV-58 Vaccine 7,699 322 1.30 11.2 (3.5 to 23.8) 0.1271 7,617 409 1.68 18.8 (7.3 to 28.9) 0.0017 87 27.0 29.0
Control 7,702 362 1.46 7,632 502 2.06 140 38.7 41.1
HPV-59 Vaccine 7,711 338 1.36 7.4 (7.7 to 20.4) 0.3156 7,618 491 2.02 9.2 (2.8 to 19.8) 0.1143 153 45.3 48.7
Control 7,722 365 1.47 7,631 541 2.23 176 48.2 51.6
a No., number of evaluable women in each group; Cases, number of women reporting at least one event in each group; Rate, number of cases divided by the sum of the follow-up
period (per 100 woman years) (the follow-up period started on the day after the third vaccine dose); VE (%), vaccine efficacy (conditional exact method). Women had to be DNA
negative for the corresponding HPV type at months 0 and 6.  cases, absolute difference of number of cases number of cases determined by the alternative algorithm number
of cases determined by the protocol-specified algorithm; %  cases, relative difference of number of cases  100/(number of cases determined by the protocol-specified
algorithm); %  rates, relative difference of rates (rate determined by the alternative algorithm rate determined by the protocol-specified algorithm) 100/(rate determined
by the protocol-specified algorithm).
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cogenic HPV types not targeted by the vaccine may eventually
take over the niche vacated by the eradication of vaccine types,
type replacement has not been found in the sizeable PATRICIA
trial or elsewhere, although only low-vaccine-coverage cohorts
have been analyzed to date (15, 23). Thus, at present a diagnos-
tic artifact is the most plausible explanation.
It is relevant to note that the HPV types detected by the broad-
spectrum SPF10 PCR-DEIA/LiPA25 system (14 oncogenic and 11
nononcogenic HPV types) but not covered by the highly sensitive
MPTS12 RHA (9 oncogenic HPV types) would still be detected by
the combination of assays included in the alternative testing
algorithm if the copy numbers were high enough. As our aim
was to interrogate differences between the protocol-specified
and alternative algorithms, we have not reported results for the
individual oncogenic HPV types not covered by the MPTS12
RHA (i.e., types 51, 56, 66, and 68), although data for these
genotypes are included in composite endpoints for combined
oncogenic HPV types.
In summary, we believe that the negative estimates of VE
against persistent infection with some nonvaccine oncogenic HPV
types in PATRICIA (e.g., HPV-58) were likely due to the short-
comings of the HPV DNA PCR testing methodology used in the
original protocol-specified analyses. Inclusion of the MPTS12
RHA in the testing algorithm reveals a higher sensitivity of detec-
tion for some nonvaccine oncogenic HPV types, while the previ-
ous algorithm underestimated VE for virological endpoints with
some of these HPV types. Overall, these exploratory results do not
change the previously reported conclusions relating to the pri-
mary and secondary objectives of PATRICIA (11, 12, 14), which
are still valid since the protocol-specified HPV DNA testing algo-
rithm was used. However, our results may be useful to inform the
choice of assays included in HPV DNA testing algorithms for the
evaluation of virological endpoints in future studies. This is im-
portant in the evaluation of the efficacies of currently licensed and
next-generation vaccines against oncogenic HPV types other than
16 and 18 (24, 25) and is particularly pertinent to geographic
regions or ethnic groups that have an increased incidence of less
common oncogenic HPV types.
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